Chimera Bioengineering: Funding, Investors & Team (Sep 2026)
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w
Chimera Bioengineering has raised $7.5M across 1 funding round on record, the most recent a Grant of $7.5M announced in Apr 2022.
That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Chimera Bioengineering Company Profile and Key Stats
Latest funding round on record: Apr 2022.
Chimera Bioengineering Funding Rounds
Chimera Bioengineering Founders and Leadership Team
Contact details for the Chimera Bioengineering team: 1 of 1 has an email address on file.
Start 14-day free trial →Chimera Bioengineering Funding Compared to Other Biotechnology Startups
Chimera Bioengineering's latest round of $7.5M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Chimera Bioengineering in Biotechnology and South San Francisco
Companies Similar to Chimera Bioengineering
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Chimera Bioengineering Funding FAQs
What does Chimera Bioengineering do?
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w
How much funding has Chimera Bioengineering raised?
Chimera Bioengineering has raised $7.5M across 1 round on record. The most recent is a Grant of $7.5M announced in Apr 2022.
When did Chimera Bioengineering last raise funding?
Chimera Bioengineering's most recent funding round on record is a Grant of $7.5M, announced in Apr 2022.
Who is the CEO of Chimera Bioengineering?
Vlad Hogenhuis is listed as CEO at Chimera Bioengineering.
Where is Chimera Bioengineering headquartered?
Chimera Bioengineering is based in South San Francisco, California, United States.
How many employees does Chimera Bioengineering have?
Chimera Bioengineering is in the 11-50 employee band.
How does Chimera Bioengineering's funding compare to other Biotechnology startups?
Chimera Bioengineering's latest round of $7.5M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Chimera Bioengineering Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Chimera Bioengineering is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.